- Home
- JELD vs CRBU Comparison
JELD vs CRBU Comparison
Compare JELD & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | CRBU |
|---|---|---|
| Founded | 1960 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 166.6M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JELD | CRBU |
|---|---|---|
| Price | $1.22 | $1.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.43 | ★ $10.75 |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | $2.06 | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $1.38 |
| 52 Week High | $6.98 | $3.53 |
Technical Indicators
Market Signals| Indicator | JELD | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 47.66 |
| Support Level | $0.93 | $1.73 |
| Resistance Level | $2.15 | $2.02 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 9.15 | 45.45 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.